Literature DB >> 17882660

Temozolomide treatment of an adult with a relapsing medulloblastoma.

X Durando1, Emilie Thivat, Olivier Gilliot, Bernard Irthum, Pierre Verrelle, Catherine Vincent, Jacques-Olivier Bay.   

Abstract

Temozolomide is an oral cytotoxic agent that has demonstrated its interest in high grade glioma tumors. This drug can be used either concomitantly with radiotherapy or as chemotherapy. The prognosis of relapsing medulloblastoma is poor and treatment is often difficult, especially after radiotherapy. Here, we report the use of temozolomide in an adult presenting relapsing medulloblastoma. An initial partial response was observed for this previously heavily treated patient. This observation suggests this drug may be useful in medulloblastoma, either as conventional chemotherapy or for use together with radiotherapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17882660     DOI: 10.1080/07357900701518164

Source DB:  PubMed          Journal:  Cancer Invest        ISSN: 0735-7907            Impact factor:   2.176


  9 in total

Review 1.  Updates on Management of Adult Medulloblastoma.

Authors:  Nazanin Majd; Marta Penas-Prado
Journal:  Curr Treat Options Oncol       Date:  2019-06-24

Review 2.  The role of radiotherapy in adult medulloblastoma: long-term single-institution experience and a review of the literature.

Authors:  M Balducci; S Chiesa; D Chieffo; S Manfrida; N Dinapoli; A Fiorentino; F Miccichè; V Frascino; C Anile; V Valentini; B De Bari
Journal:  J Neurooncol       Date:  2011-07-31       Impact factor: 4.130

3.  Temozolomide is an active agent in children with recurrent medulloblastoma/primitive neuroectodermal tumor: an Italian multi-institutional phase II trial.

Authors:  Graziella Cefalo; Maura Massimino; Antonio Ruggiero; Giuseppe Barone; Vita Ridola; Filippo Spreafico; Paolo Potepan; Massimo E Abate; Maurizio Mascarin; Maria Luisa Garrè; Giorgio Perilongo; Enrico Madon; Cesare Colosimo; Riccardo Riccardi
Journal:  Neuro Oncol       Date:  2014-01-30       Impact factor: 12.300

4.  Relapse in medulloblastoma: what can be done after abandoning high-dose chemotherapy? A mono-institutional experience.

Authors:  Maura Massimino; Michela Casanova; Daniela Polastri; Veronica Biassoni; Piergiorgio Modena; Emilia Pecori; Elisabetta Schiavello; Marco Vajna De Pava; Alice Indini; Paolo Rampini; Dario Bauer; Serena Catania; Marta Podda; Lorenza Gandola
Journal:  Childs Nerv Syst       Date:  2013-04-18       Impact factor: 1.475

Review 5.  Management of recurrent medulloblastoma in adult patients: a systematic review and recommendations.

Authors:  Xanthoula Kostaras; Jacob C Easaw
Journal:  J Neurooncol       Date:  2013-07-23       Impact factor: 4.130

6.  Efficacy of temozolomide for recurrent embryonal brain tumors in children.

Authors:  Chung-Hao Wang; Ting-Rong Hsu; Tai-Tong Wong; Kai-Ping Chang
Journal:  Childs Nerv Syst       Date:  2008-12-24       Impact factor: 1.475

7.  A pediatric phase 1 trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: a Children's Oncology Group phase 1 consortium study.

Authors:  Trent R Hummel; Lars Wagner; Charlotte Ahern; Maryam Fouladi; Joel M Reid; Renee M McGovern; Matthew M Ames; Richard J Gilbertson; Terzah Horton; Ashish M Ingle; Brenda Weigel; Susan M Blaney
Journal:  Pediatr Blood Cancer       Date:  2013-03-28       Impact factor: 3.167

8.  Medulloblastoma in an Adult With Late Extraneural Metastases to the Mediastinum.

Authors:  Abhimanyu Ghose; John C Morris; John C Breneman; James Essell; Jiang Wang; Sadia Benzaquen
Journal:  J Investig Med High Impact Case Rep       Date:  2014-04-17

9.  Recurrent extraneural sonic hedgehog medulloblastoma exhibiting sustained response to vismodegib and temozolomide monotherapies and inter-metastatic molecular heterogeneity at progression.

Authors:  Gregorio J Petrirena; Julien Masliah-Planchon; Quentin Sala; Bertrand Pourroy; Didier Frappaz; Emeline Tabouret; Thomas Graillon; Jean-Claude Gentet; Olivier Delattre; Olivier Chinot; Laetitia Padovani
Journal:  Oncotarget       Date:  2018-01-03
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.